First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

AIMS: To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL)‐17A and IL‐17F, in subjects with mild plaque psoriasis. METHODS: Randomized, double‐blind, first‐in‐human study of bimek...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatt, Sophie, Helmer, Eric, Haier, Birgit, Strimenopoulou, Foteini, Price, Graham, Vajjah, Pavan, Harari, Olivier A., Lambert, John, Shaw, Stevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401985/
https://www.ncbi.nlm.nih.gov/pubmed/27859546
http://dx.doi.org/10.1111/bcp.13185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401985/
https://www.ncbi.nlm.nih.gov/pubmed/27859546
http://dx.doi.org/10.1111/bcp.13185

Ejemplares similares